News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SARcode Announces Results of Phase 1 Trial of SAR 1118 Ophthalmic Solution in Healthy Adult Subjects



3/30/2009 11:49:16 AM

SAN FRANCISCO--(BUSINESS WIRE)--SARcode Corporation announced today the results of its Phase 1 randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers. SAR 1118 was well-tolerated and demonstrated a favorable safety profile when administered by topical ocular instillation up to three times daily at dose strengths of up to 5%.

Read at BioSpace.com

Related News

comments powered by Disqus
SARcode
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES